Syndax Pharmaceuticals SNDX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $64.86M-5.6% | $68.73M+49.8% | $45.87M+20.8% | $37.96M+89.4% | $20.04M+161% | ||
| $58.85M-25.2% | $78.64M+39.7% | $56.28M-9.6% | $62.23M+1.0% | $61.64M-5.9% | ||
| —— | $44.92M0.0% | $44.92M0.0% | $44.92M0.0% | $44.92M+48.6% | ||
| $37.59M— | —— | $44.92M+2.5% | $43.81M+6.8% | $41.03M— | ||
| $99.07M-24.5% | $131.28M+27.1% | $103.3M-3.7% | $107.31M+3.4% | $103.8M-0.2% | ||
| -$34.2M+45.3% | -$62.55M-8.9% | -$57.43M+17.2% | -$69.35M+17.2% | -$83.76M+13.1% | ||
| -52.7%+38.3pp | -91%+34.2pp | -125.2%+57.5pp | -182.7%+235pp | -417.9%+837pp | ||
| $0— | $0— | $0-100% | $4K+100% | $2K+102% | ||
| -$8.47M-55.0% | -$5.47M-66.2% | -$3.29M-31.9% | -$2.49M-129% | -$1.09M-150% | ||
| $0— | —— | $0— | $0— | $0— | ||
| -$42.67M+37.3% | -$68.01M-12.0% | -$60.72M+15.5% | -$71.85M+15.3% | -$84.85M+9.9% | ||
| -65.8%+33.2pp | -99%+33.4pp | -132.4%+56.9pp | -189.3%+234pp | -423.3%+803pp | ||
| -$0.48+38.5% | -$0.78-11.4% | -$0.70+15.7% | -$0.83+15.3% | -$0.98+10.1% | ||
| -$30.2M— | —— | —— | —— | -$83.76M— | ||
| -46.6%— | —— | —— | —— | -417.9%— | ||
| -$34.2M+45.3% | -$62.55M-8.9% | -$57.43M+17.2% | -$69.35M+17.2% | -$83.76M+13.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Syndax Pharmaceuticals's revenue?
- Syndax Pharmaceuticals (SNDX) generated $217.4M in revenue over the trailing twelve months, up 397.3% year over year.
- Is Syndax Pharmaceuticals profitable?
- Syndax Pharmaceuticals is not currently profitable: it reported a net loss of $243.2M over the trailing twelve months, a -111.9% net margin.
- What is Syndax Pharmaceuticals's earnings per share?
- Syndax Pharmaceuticals's diluted EPS over the trailing twelve months is $-2.79.
- Where does Syndax Pharmaceuticals's income statement data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
